General Information of Drug (ID: DMI7XMU)

Drug Name
CT 868 Drug Info
Indication
Disease Entry ICD 11 Status REF
Type 2 diabetes 5A11 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMI7XMU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Semaglutide DMAGFOD Type-2 diabetes 5A11 Approved [3]
Liraglutide DM3FXPS Non-insulin dependent diabetes 5A11 Approved [4]
Exenatide DMYHBKN Inflammation 1A00-CA43.1 Approved [5]
Dulaglutide DMYXBV3 Type-2 diabetes 5A11 Approved [6]
Lixisenatide DM0QJDC Type-2 diabetes 5A11 Approved [7]
Pramlintide DM0EZ9Q Type-1/2 diabetes 5A10-5A11 Approved [4]
Albiglutide DM1JEGF Type-2 diabetes 5A11 Approved [7]
Tirzepatide DMQNMAT Type 2 diabetes 5A11 Approved [8]
Efpeglenatide DMKA2PI Type-2 diabetes 5A11 Phase 3 [9]
GLP-1 DMR6YH3 Diabetic complication 5A2Y Phase 3 [3]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Retatrutide DM8WU0Q Obesity 5B81 Phase 3 [10]
LY3437943 DMN37M6 Obesity 5B81 Phase 2 [11]
AMG 133 DMSRCIS Obesity 5B81 Phase 2 [12]
SAR438335 DM7QO05 Type-2 diabetes 5A11 Phase 1 [9]
CT-388 DMWHBE5 Obesity 5B81 Phase 1 [13]
LY3532226 DM9IZG3 Type 2 diabetes 5A11 Phase 1 [14]
LY3537021 DMJUXW7 Type 2 diabetes 5A11 Phase 1 [15]
RG7685 DMPQC18 Type-2 diabetes 5A11 Discontinued in Phase 2 [16]
RG7697 DMI1XQ9 Type-2 diabetes 5A11 Discontinued in Phase 2 [17]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric inhibitory polypeptide receptor (GIPR) TTYMKBE GIPR_HUMAN Modulator [2]
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Modulator [2]

References

1 Clinical pipeline report, company report or official report of Carmot Therapeutics.
2 Clinical pipeline report, company report or official report of Carmot Therapeutics.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
4 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
5 Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
6 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
8 Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
11 LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.
12 An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023 Mar;161:170939.
13 Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.
14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
15 ClinicalTrials.gov (NCT04586907) A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
16 Company report (Roche pipeline: October 16, 2012)
17 Company report (Roche pipeline: 16 October 2014)